AtriCure offers a high-margin, clinically entrenched medtech growth platform with major upside if surgical LAA prevention becomes standard of care.
Overview
AtriCure is a specialized medtech leader in surgical Afib treatment, left atrial appendage management, and non-opioid post-operative pain therapy. Its high-margin razor-and-blade model combines installed capital equipment with recurring single-use clamps, clips, and probes. The U.S. remains the dominant revenue engine, contributing 82.3% of Q1 2026 sales. Surgeons favor AtriCure for clinical evidence, procedural efficiency, and integrated training, making the company a deeply embedded standard in cardiothoracic operating rooms.